{{Rsnum
|rsid=437943
|Chromosome=4
|position=35370476
|Orientation=minus
|GMAF=0.4812
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 44.6 | 49.1 | 6.2
| HCB | 41.7 | 40.9 | 17.4
| JPT | 28.6 | 47.3 | 24.1
| YRI | 0.7 | 33.6 | 65.7
| ASW | 7.0 | 29.8 | 63.2
| CHB | 41.7 | 40.9 | 17.4
| CHD | 37.7 | 50.0 | 12.3
| GIH | 49.5 | 40.4 | 10.1
| LWK | 1.9 | 32.4 | 65.7
| MEX | 38.6 | 50.9 | 10.5
| MKK | 12.3 | 55.2 | 32.5
| TSI | 45.5 | 42.6 | 11.9
| HapMapRevision=28
}}{{GWAS Summary
|SNP=rs437943
|PubMedID=18615156
|Condition=Treatment response to TNF antagonists
|Gene=CENTD1
|Risk Allele=G
|pValue=4.00E-006
|OR=NA
|95CI=
|OA=1
}}

{{PharmGKB
|RSID=rs437943
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:18615156
|Annotation=This variant is significantly associated with the efficacy of anti-TNF treatment in rheumatoid arthritis (Adjusted P-value: 0.000004; OR: 4.6 (1.8, 12.3)). The study is a genome-wide association study using the Illumina HapMap300 SNP chip on 89 RA patients prospectively followed after beginning of anti-TNF therapy.
|Drugs=adalimumab; etanercept; infliximab
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Curated
|PharmGKB Accession ID=PA162928821
}}

{{PharmGKB
|RSID=rs437943
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:18615156; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in Rheumatoid Arthritis (Initial Sample Size: 89 cases; Replication Sample Size: NR; Risk Allele: rs437943-G). This variant is associated with Treatment response to TNF antagonists.
|Drugs=
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356479
}}

{{PMID|20423481|OA=1
}} Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs437943
|overall_frequency_n=74
|overall_frequency_d=128
|overall_frequency=0.578125
|n_genomes=45
|n_genomes_annotated=0
|n_haplomes=64
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}